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Oxaliplatin therapy of colorectal cancer induces a dose-dependent neuropathic syndrome in 50% of
patients. Pharmacological treatments may offer limited relief; scientific efforts are needed for new
therapeutic approaches. Therefore we evaluated in a preclinical setting the pain relieving properties of
mesenchymal stem cells and its secretome. Rat adipose stem cells (rASCs) were administered in a rat
model of oxaliplatin-induced neuropathy.
A single intravenous injection of rASCs reduced oxaliplatin-dependent mechanical hypersensitivity to
noxious and non-noxious stimuli taking effect 1 h after administration, peaking 6 h thereafter and lasting
5 days. Cell-conditioned medium was ineffective. Repeated rASCs injections every 5 days relieved pain
each time with a comparable effect. Labeled rASCs were detected in the bloodstream 1 and 3 h after
administration and found in the liver 24 h thereafter. In oxaliplatin-treated rats, the plasma concen-
tration of vascular endothelial growth factor (pan VEGF-A) was increased while the isoform VEGF165b
was upregulated in the spinal cord. Both alterations were reverted by rASCs. The anti-VEGF-A mono-
clonal antibody bevacizumab (intraperitoneally) reduced oxaliplatin-dependent pain. Studying the pe-
ripheral and central role of VEGF165b in pain, we determined that the intraplantar and intrathecal
injection of the growth factor induced a pro-algesic effect. In the oxaliplatin neuropathy model, the
intrathecal infusion of bevacizumab, anti-rat VEGF165b antibody and rASCs reduced pain.
Adult adipose mesenchymal stem cells could represent a novel approach in the treatment of neuro-
pathic pain. The regulation of VEGF-A is suggested as an effective mechanism in the complex response
orchestrated by stem cells against neuropathy.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Oxaliplatin is an antineoplastic drug primarily used in the
treatment of metastatic colorectal cancer alone or in combination
with other agents (De Gramont et al., 1997; Diaz-Rubio et al., 1998).thyl)benzoyl)amino)tetrame-
eritoneal; i.t., intrathecal; i.v.,
rat adipose stem cells; PAG,
ychology, Drug Research and
icology Section, University of
sare Mannelli).Unlike other platinum compounds, oxaliplatin infusion is associ-
ated with mild nephron-and hematological toxicity with no grade
3e4 anemia, thrombocytopenia or neutropenia (Diaz-Rubio et al.,
1998; Holmes et al., 1998; Souglakos et al., 2002). Nevertheless,
oxaliplatin administration induces the development of neuropathic
syndrome in 50% of patients receiving a total cumulative dose
higher than 1000 mg/m2 over four cycles or more of therapy (De
Gramont et al., 2000; Kannarkat et al., 2007). Symptoms of oxali-
platin neurotoxicity include altered pain threshold, paresthesia and
dysesthesia that affect both lower and upper extremities in a
characteristic “glove and stocking” distribution (Kannarkat et al.,
2007; Wolf et al., 2008) resulting in impaired quality of life in
cancer survivors since symptoms do not remit after chemotherapy
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(Hershman et al., 2014). Therefore, efforts are still in progress to
study the basis of oxaliplatin-induced neuropathic pain in pre-
clinical experimental models. In animals, neuropathic syndrome
induced by oxaliplatin is characterized by important alterations to
the peripheral and central nervous systems resulting in aberrant
somatosensory processing (Cavaletti et al., 2001; Di Cesare
Mannelli et al., 2013).
There is increasing interest in adult mesenchymal stem cells
(MSCs) for the treatment of different degenerative and ischemic
pathologies as well as neuropathic pain. Adult MSCs are not only a
pluripotent cellular source for replacing injured tissues but also
represent a source of neuroprotective and anti-inflammatory me-
diators. MSCs are able to modulate the inflammatory cascade
associated with immune-related diseases, such as rheumatoid
arthritis (Gonzalez-Rey et al., 2010), but also painful neuropathies
consequent to nerve trauma (Sacerdote et al., 2013;Watanabe et al.,
2015), or to metabolic alterations (Shibata et al., 2008). MSCs can be
isolated from fetal liver, umbilical cord blood, bone marrow and
stromal vascular cell fraction of adipose tissue which is an abun-
dant and easily accessible source. Adipose derived stem cells (ASCs)
are characterized by a phenotypic profile and differentiating
capability similar to bone marrow or embryonal derived MSCs
(Kern et al., 2006; Baglioni et al., 2009). Several studies have
demonstrated that ASCs are able to efficiently differentiate toward
adipogenic- chondrogenic- neurogenic- osteogenic-like cells
(Quirici et al., 2010; Choudhery et al., 2013), and to modulate bio-
molecular signals (Gonzalez-Rey et al., 2010; Sacerdote et al., 2013;
Nasef et al., 2008; Yoo et al., 2009). In particular, vascular endo-
thelial growth factor (VEGF), epidermal growth factor (EGF) and the
transforming growth factor-beta 1 (TGF-b1) belong to the stem cell
secretome (Ribeiro et al., 2012; Salgado et al., 2010) and these
growth factors have been related to pain modulation and neuro-
protection (Kiguchi et al., 2014; Maiese, 2015; Wang et al., 2015).
The purpose of this study was to evaluate the effect of rat ASCs
(rASCs) in a rat model of oxaliplatin-induced neuropathy by
measuring their capability of relieving pain. We also evaluated the
rASCs fate in the body and the concentration of typical stem cell-
derived mediators as possible explanation of cell effectiveness.
2. Materials and methods
2.1. Animals
For all the experiments described below, male Sprague-Dawley
rats were used. Rats weighting approximately 550e600 g were
employed for rASCs isolation while for functional and behavioral
experiments animals weighed 200e250 g. All animal manipula-
tions were carried out according to the Directive 2010/63/EU of the
European parliament and of the European Union council on the
protection of animals used for scientific purposes. Experiments
involving animals have been reported according to ARRIVE guide-
lines (McGrath and Lilley, 2015).
2.2. Cell preparation and characterization
Retrosternal, thighs and aortic fat pads from Wistar rats
weighing approximately 550e600 g, were harvested and digested
with collagenase type I. The sample was filtered through a 100 mm
mesh filter to remove debris and at 700  g for 10 min. The pellet
was suspended and plated in Nutrient mixture F-12 Ham supple-
mented with 20% FBS and 1% penicillin-streptomycin and incu-
bated at 37 C in 5% CO2 atmosphere. Immunophenotypical analysis
of cultured cells was performed by using the FITC-, PE-, APC or
eFluor 450- conjugated monoclonal antibodies (mAbs) againstCD90, CD79a, CD29, CD45 respectively. In all experiments, only
cells at P2 of culture were used. Detailed procedures used for rASCs,
rat coronary endothelial cells (Failli et al., 2000) and rat aortic
smooth muscle cells (Mazzetti et al., 2003) were described in the
Supplementary material.2.3. Oxaliplatin-induced neuropathic pain model
Neuropathic pain was induced by i.p. injection of 2.4 mg kg1
oxaliplatin dissolved in a 5% glucose and administered i.p. for 4
consecutive days every week for 2 weeks (Cavaletti et al., 2001; Di
Cesare Mannelli et al., 2013 with minor modifications). Control rats
received an equal volume of 5% glucose. During treatments, general
conditions of animals were evaluated. On day 13, body weight was
decreased in comparison to control (264 ± 8 vs 301 ± 10), as well
the number of red blood cells (3.8  106 ± 0.6  106 vs
6.8  106 ± 1  106, P < .05).2.4. rASCs administration
For i.v. administration, cells were suspended in 400 mL of DMEM
without phenol red and with 500 I.U. heparin and injected into the
tail vein in the amount of 2  106 (5  103 cells/mL) per rat; control
rats received the same amount of vehicle or rASCs conditioned
medium (i.p., see the next chapter for conditioned medium
preparation).
Animalswere randomly divided into the following experimental
groups of 10e12 rats each, receiving according to Fig. 1:
- control þ DMEM: control (oxaliplatin vehicle i.e. 5% glucose),
DMEM (rASCs medium);
- oxaliplatin þ DMEM: oxaliplatin, DMEM at day 13 (single
administration) or DMEM at days 6, 13, 17 and 20 (repeated
administrations).
- control þ rASCs: control (oxaliplatin vehicle), 2  106 rASCs at
day 13 (single administration),
- oxaliplatin þ rASCs: oxaliplatin, 2  106 rASCs at day 13 (single
administration) and 2  106 rASCs at day 6, 13, 17 and 20
(repeated administrations); oxaliplatin þ conditioned medium:
oxaliplatin, conditioned medium (3.5 mL i.p., see below) at day
13 (single administration)
- control þ labeled rASCs: control (oxaliplatin vehicle), 2  106
labeled rASCs at day 13 (single labeled administration)
- oxaliplatinþ labeled rASCs: oxaliplatin, 2 106 labeled rASCs at
day 13 (single labeled administration).
In a separated experiment rASCs (75  103/15 mL; 5  103 cells/
mL in saline) were intrathecally infused in control and oxaliplatin-
treated rats (on day 13 after the beginning of oxaliplatin treatment).
rASCs conditioned medium treatment and rASCs labeling were
performed as described in the Supplementary material.2.5. VEGF165b, bevacizumab and anti-rat-VEGF165b antibody
administration
Human recombinant VEGF165b in physiological solution was
administered intraplantarly in the right paw. Bevacizumab (saline)
was injected i.p. in control and oxaliplatin treated groups (on day 13
after the beginning of oxaliplatin treatment). In separated experi-
ments VEGF165b, bevacizumab and an anti-rat-VEGF165b antibody
were injected i.t. according to Mestre et al. (1994) (more informa-
tion in the Supplementary material).
Fig. 1. Rat ASCs administrations in a neuropathy model induced by oxaliplatin. Representative scheme of single (on day 13), single labeled (on day 13) and repeated (on day 6, 13, 17
and 20) rASCs or DMEM administrations in rats repeatedly treated with oxaliplatin. rASCs (2  106) were injected into the tail vein in 400 mL of DMEM containing 500 I.U. heparin.
Oxaliplatin (2.4 mg kg1) was administered intraperitoneally (i.p.) for 4 consecutive days every week for 2 weeks. Control rats received 5% glucose.
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The hypersensitivity to a noxious mechanical stimulus of rats
was determined with an analgesimeter, according to the method
described by Leighton et al. (1998). An electronic Von Frey hair unit
was used to evaluate the response to non noxious mechanical
stimulus accordingly with Di Cesare Mannelli et al. (2013) and
Sakurai et al. (2009). Weight bearing changes were measured using
an incapacitance apparatus detecting changes in postural equilib-
rium after a hind limb injury (Bove et al., 2003; Di Cesare Mannelli
et al., 2014). Data were expressed as the difference between the
weight applied on the limb contralateral to the injury and the
weight applied on the ipsilateral one (D Weight).
2.7. Ex vivo analyses
Blood and organ were collected as described in the Supple-
mental Experimental Procedures. Cytokines, growth factors, pain
related peptides were measured into plasma samples of groups
using quantitative Milliplex Luminex. Data were collected and
analyzed using a BioPlex 200 instrument equipped with Bio-
Manager analysis software. Nerve growth factor (NGF) was
measured by ELISA kit. Western blot analysis were performed on
DRGs, lumbar spinal cord, PAG, thalamus, and primary somato-
sensory (S1) cortex or in samples obtained from cell cultures of
rASCs or rat coronary endothelial cells (Failli et al., 2000). Ponceau
stained membranes were used as loading control for plasma sam-
ple analysis. a-tubulin or GAPDH normalization was performed for
nervous tissue samples, rASCs and rat coronary endothelial cells.
Values were reported as percentages of controls arbitrarily fixed at
100%.
2.8. Statistical analysis
Results were expressed as means ± S.E.M. and the analysis of
variance was performed by ANOVA test. A Bonferroni's significant
difference procedure was used as a post hoc comparison. P values
less than 0.05 were considered significant. Data were analyzed
using the ‘‘Origin 8.100 software.
3. Results
3.1. Cell cytocharacterization
Different sources of rASCs were evaluated by processing rat
thighs, retrosternal and aortic fat pads. The stemness of isolatedcells was assessed in terms of percentage of CD29, CD90-positive
cells, as markers for mesenchymal stem cells, and CD45, CD79a-
positive cells, as markers for hematopoietic stem cells. All cell lines
obtained from different anatomical fat pads exhibited the typical
phenotype of mesenchymal stem cells (CD90þ CD29þ CD45
CD79a) (Supplementary material, Table S1). The retrosternal fat
pad held a higher percentage of CD90and CD29-positive cells
(83.3% and 92.5%, respectively) than thighs (86.7% and 87.6%
respectively) and aortic fat pads (59.9% and 88.7% respectively). The
expression of CD45 and CD79a was lower in retrosternal fat-
derived cells (7%) than in thighs and aortic fat-derived cells (12%
and 11% respectively) (Supplementary material, Table S1). Based on
these results retrosternal-derived rASCs were chosen to perform all
experiments. Several cell lines at different serial passages (from P1
to P4) and after thawing and culture until confluence were cyto-
characterized by flow cytometry (Supplementary material,
Table S2). Rat ASCs at P2 showed the better stemness phenotype
and cell cryopreservation did not change it. On these bases, retro-
sternal fat pad rASCs at P2 were used for in vivo experiments.
Supplemental information reported in Fig. S1 shows the surface
positive CD90/CD29 and negative CD79a/CD45 markers as indexes
of mesenchymal phenotype of a representative rASCs preparation
(P2). There were 91% CD90 positive cells which also expressed
CD29 (Supplementary information, Fig. S1, panel A) and 99% of the
CD79a and CD45 negative cells (Supplementary material, Fig. S1,
panel B). In order to highlight mesenchymal characteristics, rASCs
were cultured in vitro and differentiated under specific conditions
to mesenchymal cell lineages such adipocytes and osteocytes
(Supplementary material, Fig. S1, panel C and D).
3.2. Neuropathic pain measurements
Neuropathic pain was induced in rats by repeated administra-
tions of oxaliplatin (Fig. 1). On day 13, the response of oxaliplatin-
treated rats to a noxious mechanical stimulus (Paw pressure test)
was altered and the weight tolerated on the posterior paw signif-
icantly decreased from the control value of 64.1 ± 1.6 g
(control þ DMEM) to 43.4 ± 0.6 g for oxaliplatin-treated rats
(oxaliplatinþ DMEM) (Fig. 2). On the same day, 2  106 rASCs were
injected into the caudal vein of control þ rASCs and
oxaliplatin þ rASCs groups. Rat ASCs induced a significant reduc-
tion of oxaliplatin-induced hypersensitivity 1 h after injection
which peaked at 6 h (Fig. 2). The effect of rASCs lasted at least 48 h.
In control rats the caudal vein rASCs administration (2  106) did
not alter pain sensitivity. Moreover, the administration of rASCs
conditioned medium was ineffective in reducing pain in
Fig. 2. Effect of rASCs administration on pain threshold due to noxious stimulus in
oxaliplatin-induced neuropathic rats. Oxaliplatin (2.4 mg kg1 i.p.) was administered
for 4 consecutive days on weeks 1 and 2. On day 13, 2  106 rASCs (suspended in
400 mL of DMEM containing 500 U.I. heparin), were injected into the tail vein of the
control þ rASCs and oxaliplatin þ rASCs groups. Other groups received DMEM (i.v.) or
rASCs conditioned medium (i.p.) as indicated. For more details, see methods. The pain
threshold was evaluated through the paw pressure test (measuring the weight toler-
ated on the paw) at different time (1e48 h). Each value represents the mean ± SEM of
10 rats per group, performed in 2 different experimental sets. ^^ P < .01 vs
control þ DMEM; **P < .01 vs oxaliplatin þ DMEM.
Fig. 3. The effect of repeated rASCs administration on the pain threshold of noxious
and non-noxious stimuli in oxaliplatin-induced neuropathic rats. A) Paw pressure and
B) Von Frey tests. Oxaliplatin (2.4 mg kg1 i.p.) was administered for 4 consecutive
days on weeks 1 and 2. On day 6, 13, 17 and 20, 2  106 rASCs (suspended in 400 mL of
DMEM containing 500 U.I. heparin) were injected into the tail vein. Each value rep-
resents the mean ± SEM of 12 rats per group, performed in 2 different experimental
sets. Values obtained in oxaliplatin þ DMEM treated rats were significantly reduced as
compared to those of control þ DMEM animals starting from the 4th day until the 27th
day (A, Paw pressure) and until the 21st (B, Von Frey). The significance in the
oxaliplatin þ rASCs group is shown with stars. *P < .05 and **P < .01 vs
oxaliplatin þ DMEM.
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exert the antineuropathic effect.
In order to better understand the effect of rASCs on neuropathic
pain repeated administrations of rASCs were performed (scheme in
Fig. 1). As shown in Fig. 3, rASCs determined a significant, compa-
rable reduction of hypersensitivity induced by mechanical noxious
(Paw pressure test; Fig. 3A) and non-noxious (Von Frey test; Fig. 3B)
stimuli each time that cells were administered. This analgesic effect
lasted for 5 days after injection. To validate the specificity of the
stem cellular therapy, 2  106 rat aortic smooth muscle cells were
i.v. infused in oxaliplatin-treated rats. No effects were revealed
(data not shown).
3.3. Fate of rASCs and cytokines and growth factors measurement
In order to track the injected rASCs, CMTMR-labeled cells were
identified by flow cytometry analysis in the blood and organs of
oxaliplatin-treated (oxaliplatin þ labeled rASCs) or control rats
(control þ labeled rASCs). CMTMR-labeled rASCs were detectable 1
and 3 h after cell administration in the blood of both groups,
whereas 6 h later labeled cells were at the lowest limit of flow
cytometry sensitivity (Supplementary material Table S3). After
24 h, only a small percentage of cells were detectable in the liver of
both groups (0.02 ± 0.007%), whereas no CMTMR-labeled rASCs
were revealed in the lung, DRG or spinal cord. Mechanical hyper-
sensitivity (Paw pressure test) of animals receiving labeled rASCs
was very similar to that of rats receiving unlabeled cells.
To evaluate the biomolecular response evoked by rASCs, plas-
matic concentrations of IL-1a, IL-6, IP-10, TNF-a, pan VEGF-A, EGF,
a-MSH, b-Endorphin, Substance P, TGF-b1 and NGF were assayed.
As shown in Fig. 4A, pan VEGF-A significantly increased in
oxaliplatin-treated rats compared to control animals. Twenty four h
after rASCs administration to oxaliplatin-treated rats, VEGFconcentrations significantly decreased. The administration of rASCs
to control animals did not influence VEGF concentrations (Fig. 4A).
TGF-b1 and EGF concentrations were not found to be altered in any
group when compared to the control one (data not shown). No
other analyzed peptides were detectable in the plasma.
3.4. VEGF-R1 expression in rASCs
The study of the relevance of VEGF in rASCs activity begun by
the evaluation of the protein expression of the VEGF specific re-
ceptor VEGF-R1. As shown in Fig. 4B, rASCs were characterized by
the expression of VEGF-R1 in a quantity comparable to that
detected in rat coronary endothelial cells.
3.5. Bevacizumab effects on oxaliplatin-treated rats
In the described rat model of oxaliplatin-induced neuropathy,
increasing i.p. doses of bevacizumab (1e15 mg kg1), reduced
mechanical hypersensitivity in a dose dependent manner starting
15 min after administration (Fig. 5). The effect of bevacizumab
Fig. 4. A) Pan VEGF-A plasma concentration. Oxaliplatin (2.4 mg kg1 i.p.) was
administered for 4 consecutive days on weeks 1 and 2. On day 13, 2  106 rASCs
(suspended in 400 mL of DMEM containing 500 I.U. heparin) were injected into the tail
vein of rats of the control þ rASCs and oxaliplatin þ rASCs groups. Before, and at 3, 6, 9,
24 and 48 h after i.v. cell administration, the blood was collected. VEGF was measured
in plasma by Bioplex kits. Each value represents the mean ± SEM of 4 rats per group,
performed in 2 different experimental sets. ^P < .05, ^^ P < .01 and ^^ ^P < .001 vs
control þ DMEM at the same time. B) VEGF-R1 expression in rASCs. Protein fractions
(40 mg) from rat endothelial (rCEs) or adipose stem cells (rASCs) were analyzed in
duplicate by western blot in order to evaluate VEGF-R1 level. Representative blot are
shown, as well as their respective densitometric analysis. GAPDH normalization was
performed. Each value represents the mean of 4 preparations, performed in two
different experimental sets.
Fig. 5. Effect of bevacizumab against oxaliplatin-induced hypersensitivity. Oxaliplatin
(2.4 mg kg1 i.p.) was administered for 4 consecutive days on weeks 1 and 2. On day
13, bevacizumab (1, 5 and 15 mg kg1) was injected i.p. in control and oxaliplatin
treated groups. Other groups received saline. A) The response to mechanical noxious
stimulus was evaluated by the paw pressure test over time (0 mine24 h). B) The
response to mechanical non noxious stimulus was evaluated by the Von Frey test over
time (0 mine24 h) Each value represents the mean ± SEM of 10 rats per group, per-
formed in 2 different experimental sets. ^^ P < .01 vs control þ vehicle, **P < .01 vs
oxaliplatin þ vehicle.
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at 3 h. Lower doses of bevacizumab showed a similar time-course
with a lower efficacy, peaking 1 h after administration and lasting
up to 3 h. Comparable results were obtained with a non noxious
mechanical stimulus (Von Frey test; Fig. 5B), all dosages showing
effectiveness in a time span of between 30 min and 3 h (Fig. 5B). In
control animals, bevacizumab (15 mg kg1, i.p.) did not alter the
pain threshold (Fig. 5, panels A and B).3.6. Intraplantar recombinant VEGF165b effects on normal pain
threshold
Aimed to evaluate the pro-nociceptive potential of VEGF, we
injected VEGF165b, a splice variant of VEGF-A involved in pain
modulation (Hulse et al., 2014), into the right paw of naïve rats.
Fig. 6A shows the decrease of the pain threshold evaluated by the
stimulation with a mechanical insult (Paw pressure test). Thirty
min after the intraplantar administration, recombinant VEGF165b
(10, 30 or 100 ng) dose-dependently reduced the weight tolerated
on the paw. The maximal pain perception was reached after 3 h,
24 h thereafter it returned to a level comparable to control value.
Similarly, VEGF165b evoked spontaneous pain as measured by hind
limbweight bearing alterations (Incapacitance test; Dweight is the
difference between the weight burdened on the contralateral and
the ipsilateral paw, Fig. 6B). Bevacizumab (15 mg kg1 i.p.) fully
prevented the algesic effect and significantly reduced the achiness
induced by VEGF165b (Fig. 6A and B).
Fig. 6. Effect of recombinant VEGF165b on pain threshold. Intraplantar injection. Naïve
rats were treated with 10, 30 or 100 ng of VEGF165b in comparison to vehicle (saline). A
final volume of 50 ml was administered by intraplantar injection in the right paw.
Bevacizumab (15 mg kg1 i.p.) was administered 15 min before VEGF165b. A) The
response to mechanical noxious stimulus was evaluated by the paw pressure test over
time (30 mine24 h). B) Spontaneous pain was assessed by hind limb weight bearing
alterations using an Incapacitance test that measures the postural imbalance related to
pain; data are expressed as the difference between the weight applied on the
contralateral and ipsilateral limbs to the intraplantar injection (D Weight). Each value
represents the mean ± SEM of 10 rats per group, performed in 2 different experimental
sets. ^P < .05 and ^^ P < .01 vs the same group before treatment (0 min); **P < .01 vs
30 ng VEGF165b in the absence of bevacizumab.
Fig. 7. Spinal modulation of pain: effects of VEGF165b, VEGF-A antibodies and rASCs.
Intrathecal injection. A) Naïve rats were treated with 30 or 100 ng of VEGF165b in
comparison to vehicle (saline). B) Effect of bevacizumab (45 mg) and a rat specific
antibody against VEGF165b (7.5 mg) in comparison to the effect of 75  103 rASCs after
intrathecal injection in control or oxaliplatin-treated rats (day 13). The response to a
mechanical noxious stimulus was evaluated by the paw pressure test over time
(1e48 h). Each value represents the mean ± SEM of 10 rats per group, performed in 2
different experimental sets. ^P < .05 and ^^ P < .01 vs control þ vehicle, **P < .01 vs
oxaliplatin þ vehicle.
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antibodies and rASCs
The central component of the VEGF role in pain signaling was
evaluated injecting VEGF165b intrathecally (i.t., 30 and 100 ng).
Fig. 7A shows the dose-dependent decrease of pain threshold (Paw
pressure test) 1e6 h after treatment. The relevance of central VEGF
was confirmed by the efficacy of bevacizumab i.t. (45 mg) in
reducing oxaliplatin-dependent hypersensitivity (Fig. 7B). More-
over, higher efficacy was obtained injecting i.t. 7.5 mg of the specific
antibody against VEGF165b (anti-rat-VEGF165b antibody). The effect
peaked between 30 mine1 h after injection and was lost at 24 h
(Fig. 7B). To extend the study of the central regulation of
oxaliplatin-dependent pain, 75  103 rASCs were intrathecallyinjected in oxaliplatin-treated rats. The onset was similar to that
shown by both VEGF antibodies but the effect was more long
lasting since the pain threshold was yet significantly enhanced 24 h
after treatment (Fig. 7B). Control animals treated i.t. with bev-
acizumab, anti-VEGF165b or rASCs showed a pain threshold similar
to controls treated with vehicle (data not shown).
3.8. Evaluation of VEGF165b isoform in plasma and peripheral and
central nervous system
VEGF165b was evaluated in plasma and in the peripheral and
central nervous system of control þ DMEM, oxaliplatin þ DMEM
and oxaliplatin þ rASCs groups by western blot analysis (Fig. 8).
In the plasma of the oxaliplatin þ DMEM rat group, VEGF165b
protein levels were not modified as compared to control
(control þ DMEM), whereas in oxaliplatin þ rASCs they were
decreased by 63% as compared to control þ DMEM and
Fig. 8. VEGF165b expression in plasma and nervous tissue homogenates. A) Two different concentrations (30 and 100 ng) of recombinant human (rh) VEGF165b protein were probed
with the anti-VEGF165b antibody. B-F) Oxaliplatin (2.4 mg kg1 i.p.) was administered for 4 consecutive days on weeks 1 and 2. On day 13, 2  106 rASCs (suspended in 400 mL of
DMEM containing 500 I.U. heparin) were injected into the tail vein of rats of the oxaliplatin þ rASCs group. Twenty-four hours after i.v. administration the rats were sacrificed, tissue
explanted and blood collected in order to evaluate VEGF165b level. B) Plasma, C) DRG, D) spinal cord, E) PAG, F) thalamus and G) S1 cortex representative Western blot are shown, as
well as their respective densitometric analysis. Ponceau stained membranes were used as loading control for plasma quantification. a-tubulin normalization was performed on
nervous tissue samples. In the panels, 1, 2 and 3 represent the three repetitions of controlþ DMEM group; 4, 5 and 6 represent the three repetitions of oxaliplatin þ DMEM group; 7,
8 and 9 represent the three repetitions of oxaliplatin þ rASCs group. Each value represents the mean of 10 rats per group, performed in two different experimental sets. *P < .05
versus oxaliplatin þ DMEM; ^P < .05 versus oxaliplatin þ rASCs.
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VEGF165b level was measured (Fig. 8C). In the spinal cord, VEGF165b
was increased in oxaliplatin þ DMEM rats by 43% whereas
administration of rASCs restored control values (Fig. 8D). In the PAG
oxaliplatin increased VEGF165b (about 40%) and rASC administra-
tion was ineffective (Fig. 8E). In the thalamus and cortex, VEGF165b
was not ever altered by oxaliplatin or rASC treatments (Fig. 8,
panels F and G).
To confirm antibody specificity, the anti-VEGF165b antibody was
used to probe a blot of an SDSepolyacrylamide gel loaded with
increasing quantities of recombinant human VEGF165b. Fig. 8A
shows that the antibody concentration-dependently recognized
VEGF165b. The VEGF165b-specific antibody detected a proteinwith a
molecular weight of about 23 kDa which was consistent with the
monomeric form of the growth factor. In plasma and DRG this band
was the only one detected; in other tissues it was prominent but
the antibody revealed other bands coherent with the presence of
VEGF165b homodimer (about 40 kDa) or other VEGF-A sister iso-
forms (Woolard et al., 2004; Ergorul et al., 2008; Manetti et al.,
2011).
4. Discussion
The present data describe the pain relieving efficacy of rASCs in
a rat model of oxaliplatin-induced neuropathy. The ability to
modulate the VEGF is suggested as a possible mechanism of rASC-
mediated pain control.
Adipose-derived stem cells are a class of mesenchymal stem
cells isolated from the stromal vascular cell fraction of the adipose
tissue. In ischemic, neurodegenerative and traumatic pain, their
beneficial effect seems to be dependent on their modulatory and
stimulating properties of mechanisms involved in tissue repair
(Chan et al., 2014). In several anatomical localized neuropathic pain
models (chronic constriction injury (Franchi et al., 2012); spared
nerve injury (Siniscalco et al., 2011; spinal cord injury (Watanabe
et al., 2015)), the administration of stem cells by i.v. or spinal in-
jection can reduce pain sensitivities with different time-courses
and intensities. However, to our knowledge this is the first time
that i.v. rASCs have been reported to reduce chemotherapy-induced
neuropathic pain.
As already described (Cavaletti et al., 2001; Di Cesare Mannelli
et al., 2013), repeated oxaliplatin administration evokes mechani-
cal hypersensitivity (hyperalgesia- and allodynia-like measure-
ments) starting from the 4th day of treatment. Rat ASCs
administration significantly reduces the pain threshold alteration
starting after 1 h and lasting up to 4e5 days after injection.
Repeated cell administrations determine the effect of pain relief
with the same time-course and intensity as the first one. Even if
rASCs are detected in the bloodstream from 1 to 3 h and in the liver
24 h after cell injection, their effect can last for several days, sug-
gesting that rASCs could activate long-lasting antihyperalgesic
mechanisms.
Mesenchymal stem cells can be primed to express a “medicinal
phenotype” (Caplan and Correa, 2011) following a lesion, and
secrete bioactive molecules that establish a microenvironment
sustaining a regeneration of injured tissues. Secreted bioactive
molecules can stimulate angiogenesis (Sorrell et al., 2009), inhibit
apoptosis and activate progenitor tissue-intrinsic stem cells to
divide and differentiate appropriately (Rehman et al., 2004;
Wagner et al., 2009). Evidence indicates that the modulation of
pro- and anti-inflammatory cytokines and growth factors is an
important way of explaining a possible mechanism of action of
stem cells (Gonzalez-Rey et al., 2010; Sacerdote et al., 2013; Franchi
et al., 2012; Siniscalco et al., 2011).
The implication of VEGF in nociception has been recognized inseveral forms of pain even if conflicting data in literature suggest
both pro- and anti-nociceptive effects for this growth factor. Ver-
heyen and colleagues (Verheyen et al., 2012) demonstrate that
neutralization of all endogenous VEGF isoforms, or VEGF receptor
antagonism increase pain sensitivity in paclitaxel-induced neu-
ropathy. Conversely, in chronic constriction injury rats anti-VEGF
receptor treatment alleviates neuropathic pain by decreasing the
expression of VEGF and purinergic P2X2/3 receptors in DRG neu-
rons (Lin et al., 2010); the VEGF increase in synovial fluid is corre-
lated with the degree of osteoarthritis pain (Hamilton et al., 2016).
Moreover, the plantar injection of VEGF-A dose-dependently in-
creases hypersensitivity to Von Frey mechanical and noxious heat
stimuli applied to the ipsilateral paw (Selvaraj et al., 2015). The
effect of VEGF-A is mediated by the activation of VEGF type 1 re-
ceptor (VEGFR1) as demonstrated using VEGFR1 antagonist,
VEGFR1 signal transduction blockers and specific DRG condition-
ally VEGFR1 lacking mice. Furthermore, VEGFR1 is involved in
tumor-associated pain in mice models of cancer-associated pain
(i.e. osteolytic sarcoma, femur implanted breast carcinoma, lung
carcinoma, pancreatic carcinoma) (Selvaraj et al., 2015). VEGF-A is
extensively alternatively spliced into two families of splice variants
(Woolard et al., 2004) and an opposite effect of VEGF165a (pro-
nociceptive) and VEGF165b (anti-nociceptive) has been noticed in
rats with saphenous nerve injury (Hulse et al., 2014) where
VEGF165a is overexpressed. VEGF165b exerts anti-nociceptive and
protective effects in steptozotocin-induced diabetic rats (Hulse
et al., 2015). On the other hand, both splice variants (VEGF165a
and VEGF165b) can prevent cisplatin induced sensory neuro-
degeneration and cell death (Vencappa et al., 2015). Also the
transplantation of neural stem cells expressing VEGF cells in a rat
sciatic nerve injury model enhances functional recovery and
remyelination and induces pain reduction (Lee et al., 2015).
In the present work, the plasmatic concentration of pan VEGF-A
undergoes a significant increase in oxaliplatin-treated rats that
could be justified by hypoxic condition (Schoch et al., 2002) here
shown as a significant decrease of red blood cells induced by the
repeated treatment with the drug (see Methods). Rat ASCs reduce
pan VEGF-A plasmatic concentration. Supporting the hypothesis
that VEGF increase plays a relevant role in the development of
neuropathic pain, our data show that the systemic administration
of the anti-VEGF antibody bevacizumab decreases oxaliplatin-
dependent pain sensitivity. VEGF165b protein expression is un-
changed in the plasma and DRG of oxaliplatin-treated rats and
administration of rASCs strongly reduces it. A different and specific
pattern is observed in peripheral and central nerve system areas.
VEGF165b increases in the spinal cord and PAG of neuropathic rats.
The treatment with rASCs reverts this VEGF165b enhancement in
the spinal cord and decreases VEGF165b level under control values.
The relevance of VEGF165b in pain perception is confirmed in naïve
rats since the intraplantar administration of the recombinant pro-
tein induces a dose-dependent, long lasting hypersensitivity to
noxious stimuli as well as spontaneous pain. The pro-nociceptive
effects of VEGF165b are prevented by systemic bevacizumab.
Interestingly, the VEGF-A role in pain possesses also a central
component since the i.t. administration of VEGF165b evokes a long
lasting hypersensitivity, confirmed by the efficacy in reducing
oxaliplatin-dependent pain-threshold alteration after i.t. injection
of both bevacizumab (anti-human-panVEGF-A antibody) and the
specific anti-rat-VEGF165b antibody. Interestingly, the i.t. injection
of rASCs evokes a complete reversion of oxaliplatin hypersensitivity
for 24 h. These results allow us to hypothesize a pharmacodynamic
relevant role of VEGF-A in oxaliplatin-induced neuropathy and in
rASCs efficacy. Since VEGF-R1 is well expressed in rASCs, the
elevated concentration of VEGF-A in plasma of oxaliplatin-treated
rats could sensitize rASCs which can influence the environment
L. Di Cesare Mannelli et al. / Neuropharmacology 131 (2018) 166e175174and execute their beneficial role after stimulation.
On the other hand, a quick regulation of VEGF concentrations is
physiologically envisaged. For instance, VEGF-A signaling can be
inhibited by an endogenously produced soluble VEGF receptor 1
(sFlt1) which lacks the transmembrane portion and the receptor
tyrosine-kinase domain but binds to VEGF-A (Shibuya, 2013;
Ferrara et al., 2003; Keyt et al., 1996). Local administration of
sFlt1 blocks VEGF-A-induced hyperalgesia and decreases tumor-
induced hyperalgesia (Selvaraj et al., 2015). Moreover, VEGF can
be degraded in endothelial cells through the internalization of the
VEGF-VEGF receptor complex and through alternate pathways such
as via low density lipoprotein receptor-related protein-1 in
conjunction with thrombospondin-1 (Greenaway et al., 2007). In
chronic wounds and some tumors, VEGF loss appears to be related
to proteolytic degradation (Lauer et al., 2000, 2002; Mineur et al.,
2007) initially dependent on plasmin cleavage (Lauer et al., 2000;
Lee et al., 2005). Adipose SCs promote the utilization of the plas-
minogen activator-plasmin axis by endothelial cells (Kachgal and
Putnam, 2011). VEGF degradation could also explain the rapid
VEGF decrease measured in our experimental conditions in relation
to the decreased pain sensitivity induced by rASCs. The regulatory
role of VEGF-A in oxaliplatin-induced pain and rASC relieving
mechanism deserves further studies.
Other growth factors, such as EGF and TGF-b, are notmodified in
plasma of oxaliplatin-treated rats or after rASCs administration,
while several cytokines and pain-related peptides are not detect-
able. It is important to note that chemokines are locally produced
by damaged, inflamed areas and can induce stem cells migration
and activation at the site of injury (Caplan and Dennis, 2006).
Oxaliplatin-induced neuropathy is a widespread model of lesions
and alterations affecting the peripheral and central nervous system,
with low inflammatory components, whereas other models of
neuropathic pain are characterized by severely damaged restricted
areas (Di Cesare Mannelli et al., 2013). Therefore, it is not surprising
that in our model, only few cytokines are involved. Further studies
will clarify these biochemical features.
In conclusion, our data demonstrate for the first time that rASCs
administration rapidly and long-lastingly decreases pain due to
oxaliplatin neurotoxicity and that rASCs pain relieving efficacy in-
volves the modulation of VEGF-A. Moreover, we prove that an in-
crease in VEGF-A is involved in oxaliplatin-induced neuropathic
pain that could be mitigated by VEGF-A antibodies. These experi-
mental results open a new therapeutic horizon for the use of
mesenchymal stem cells in the treatment of neuropathic pain.
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